2001 Data Safety Treatment 
Veriheal
AUGUST 7, 2022
New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).
CannaMD
SEPTEMBER 10, 2020
This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented. But despite these revelations, both messaging and legalities have lagged.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
AUGUST 19, 2019
The main relevant UK legislation is the Misuse of Drugs Act 1971 (the Act) and the Misuse of Drugs Regulations 2001 (as amended by the Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018) (the Regulations). No data is available regarding prescriptions written in respect of secondary care.
The Cannigma
JANUARY 13, 2023
The authors noted that while “promising data are emerging on the possible role of ECS in migraine…proper placebo-controlled trials are needed to establish a therapeutic role for cannabinoids.” Daily cannabis consumption was an effective treatment for 85% of participants. headaches per month.
The Cannigma
OCTOBER 19, 2021
These findings mirror those of a 2001 trial, in which the subjects who consumed alcohol along with cannabis “reported more episodes of euphoria and had higher plasma THC levels.” Arguably, one doesn’t need to see any scientific data to know that the mixing of cannabis and alcohol is more common with younger cannabis users.
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive.
Expert insights. Personalized for you.
109 
Let's personalize your content